
Senseonics Holdings (SENS) Stock Forecast & Price Target
Senseonics Holdings (SENS) Analyst Ratings
Bulls say
Senseonics Holdings Inc. demonstrates a strong growth trajectory, with projected total revenues expected to rise from $59.7 million in 2025 to $75.6 million in 2026, and further to $118.4 million in 2027, reflecting a robust demand for its glucose monitoring solutions. The anticipated ramp-up in revenues is further supported by expected European Union approval and a strategic partnership with Sequel Diabetes, positioning the company for significant market expansion. As the majority of revenue is generated outside the United States, the firm's global outreach complements its innovative long-term implantable glucose management technology, suggesting a positive outlook for future financial performance.
Bears say
Senseonics Holdings Inc. is anticipated to experience stagnation in revenue for the first half of 2025 primarily due to the conversion of previous U.S. contracts, suggesting challenges in scaling its business domestically. Despite having a unique product offering in long-term glucose monitoring, the company remains confronted with an unmet market need, which does not translate into immediate financial growth or revenue enhancement. The reliance on international markets for the majority of revenue could pose additional risks as fluctuations in foreign markets and regulatory environments may impact financial performance.
This aggregate rating is based on analysts' research of Senseonics Holdings and is not a guaranteed prediction by Public.com or investment advice.
Senseonics Holdings (SENS) Analyst Forecast & Price Prediction
Start investing in Senseonics Holdings (SENS)
Order type
Buy in
Order amount
Est. shares
0 shares